{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:31:30Z","timestamp":1792452690266,"version":"4.5.0"},"reference-count":101,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T00:00:00Z","timestamp":1743033600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s12325-025-03154-2","type":"journal-article","created":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T04:57:15Z","timestamp":1743310635000},"page":"2118-2134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Management of Atherosclerotic Cardiovascular Risk in Inflammatory Bowel Disease: Current Perspectives"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5620-6468","authenticated-orcid":false,"given":"Walter","family":"Masson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo","family":"Fern\u00e1ndez-Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solange","family":"Martinez-Elhelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,27]]},"reference":[{"key":"3154_CR1","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2147\/JIR.S65979","volume":"7","author":"M Fakhoury","year":"2014","unstructured":"Fakhoury M, Negrulj R, Mooranian A, Al-Salami H. Inflammatory bowel disease: clinical aspects and treatments. J Inflamm Res. 2014;7:113\u201320. https:\/\/doi.org\/10.2147\/JIR.S65979.","journal-title":"J Inflamm Res"},{"key":"3154_CR2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.65136","volume":"16","author":"C Sanchez Cruz","year":"2024","unstructured":"Sanchez Cruz C, Huerta AR, Barrientos JL, et al. Inflammatory bowel disease and cardiovascular disease: an integrative review with a focus on the gut microbiome. Cureus. 2024;16:e65136. https:\/\/doi.org\/10.7759\/cureus.65136.","journal-title":"Cureus"},{"key":"3154_CR3","doi-asserted-by":"publisher","first-page":"3012509","DOI":"10.1155\/2019\/3012509","volume":"2019","author":"DM Bunu","year":"2019","unstructured":"Bunu DM, Timofte CE, Ciocoiu M, et al. Cardiovascular manifestations of inflammatory bowel disease: pathogenesis, diagnosis, and preventive strategies. Gastroenterol Res Pract. 2019;2019:3012509. https:\/\/doi.org\/10.1155\/2019\/3012509.","journal-title":"Gastroenterol Res Pract"},{"key":"3154_CR4","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s00392-023-02291-4","volume":"113","author":"C Asenjo-Lobos","year":"2024","unstructured":"Asenjo-Lobos C, Gonz\u00e1lez L, Bulnes JB, Roque M, Venturelli PM, Mart\u00ednez RG. Cardiovascular events risk in patients with systemic autoimmune diseases: a prognostic systematic review and meta-analysis. Clin Res Cardiol. 2024;113:246\u201359. https:\/\/doi.org\/10.1007\/s00392-023-02291-4.","journal-title":"Clin Res Cardiol"},{"key":"3154_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1001\/jamacardio.2016.4494","volume":"2","author":"MJ Feinstein","year":"2017","unstructured":"Feinstein MJ, Nance RM, Drozd DR, et al. Assessing and refining myocardial infarction risk estimation among patients with human immunodeficiency virus: a study by the centers for AIDS Research Network of Integrated Clinical Systems. JAMA Cardiol. 2017;2:155\u201362. https:\/\/doi.org\/10.1001\/jamacardio.2016.4494.","journal-title":"JAMA Cardiol"},{"key":"3154_CR6","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1016\/j.jacc.2024.04.030","volume":"83","author":"MB Mortensen","year":"2024","unstructured":"Mortensen MB, Jensen JM, R\u00f8nnow Sand NP, et al. Association of autoimmune diseases with coronary atherosclerosis severity and ischemic events. J Am Coll Cardiol. 2024;83:2643\u201354. https:\/\/doi.org\/10.1016\/j.jacc.2024.04.030.","journal-title":"J Am Coll Cardiol"},{"key":"3154_CR7","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1016\/j.jacc.2020.10.027","volume":"76","author":"M Cainzos-Achirica","year":"2020","unstructured":"Cainzos-Achirica M, Glassner K, Zawahir HS, et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease: JACC Review Topic of the Week. J Am Coll Cardiol. 2020;76:2895\u2013905. https:\/\/doi.org\/10.1016\/j.jacc.2020.10.027.","journal-title":"J Am Coll Cardiol"},{"key":"3154_CR8","doi-asserted-by":"publisher","first-page":"1073984","DOI":"10.1155\/2023\/1073984","volume":"2023","author":"C Hu","year":"2023","unstructured":"Hu C, Liao S, Lv L, Li C, Mei Z. Intestinal immune imbalance is an alarm in the development of IBD. Mediat Inflamm. 2023;2023:1073984. https:\/\/doi.org\/10.1155\/2023\/1073984.","journal-title":"Mediat Inflamm"},{"key":"3154_CR9","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jaci.2019.11.003","volume":"145","author":"KL Glassner","year":"2020","unstructured":"Glassner KL, Abraham BP, Quigley EMM. The microbiome and inflammatory bowel disease. J Allergy Clin Immunol. 2020;145:16\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2019.11.003.","journal-title":"J Allergy Clin Immunol"},{"key":"3154_CR10","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.cjca.2022.05.023","volume":"38","author":"KE Boczar","year":"2022","unstructured":"Boczar KE, Beanlands R. Hearts on fire: the role of inflammation in the pathogenesis of atherosclerotic cardiovascular disease and how we can tend to the flames. Can J Cardiol. 2022;38:1553\u20137. https:\/\/doi.org\/10.1016\/j.cjca.2022.05.023.","journal-title":"Can J Cardiol"},{"key":"3154_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.atherosclerosis.2018.07.014","volume":"276","author":"P Raggi","year":"2018","unstructured":"Raggi P, Genest J, Giles JT, et al. Role of inflammation in the pathogenesis of atherosclerosis and therapeutic interventions. Atherosclerosis. 2018;276:98\u2013108. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.07.014.","journal-title":"Atherosclerosis"},{"issue":"21","key":"3154_CR12","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","volume":"359","author":"PM Ridker","year":"2008","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359(21):2195\u2013207. https:\/\/doi.org\/10.1056\/NEJMoa0807646.","journal-title":"N Engl J Med"},{"key":"3154_CR13","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","volume":"377","author":"PM Ridker","year":"2017","unstructured":"Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377:1119\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1707914.","journal-title":"N Engl J Med"},{"key":"3154_CR14","doi-asserted-by":"publisher","first-page":"1379189","DOI":"10.3389\/fcvm.2024.1379189","volume":"11","author":"W Masson","year":"2024","unstructured":"Masson W, Lobo M, Nogueira JP, Rodriguez-Granillo AM, Barbagelata LE, Siniawski D. Anti-inflammatory effect of semaglutide: updated systematic review and meta-analysis. Front Cardiovasc Med. 2024;11:1379189. https:\/\/doi.org\/10.3389\/fcvm.2024.1379189.","journal-title":"Front Cardiovasc Med"},{"key":"3154_CR15","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","volume":"38","author":"JC Tardif","year":"2019","unstructured":"Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;38:2497\u2013505. https:\/\/doi.org\/10.1056\/NEJMoa1912388.","journal-title":"N Engl J Med"},{"key":"3154_CR16","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","volume":"383","author":"SM Nidorf","year":"2020","unstructured":"Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in patients with chronic coronary disease. N Engl J Med. 2020;383:1838\u201347. https:\/\/doi.org\/10.1056\/NEJMoa2021372.","journal-title":"N Engl J Med"},{"key":"3154_CR17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2405922","author":"SS Jolly","year":"2024","unstructured":"Jolly SS, d\u2019Entremont MA, Lee SF, et al. Colchicine in acute myocardial infarction. N Engl J Med. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2405922.","journal-title":"N Engl J Med"},{"key":"3154_CR18","doi-asserted-by":"publisher","first-page":"e138","DOI":"10.1093\/cvr\/cvab231","volume":"117","author":"PM Ridker","year":"2021","unstructured":"Ridker PM. From RESCUE to ZEUS: will interleukin-6 inhibition with ziltivekimab prove effective for cardiovascular event reduction? Cardiovasc Res. 2021;117:e138\u201340. https:\/\/doi.org\/10.1093\/cvr\/cvab231.","journal-title":"Cardiovasc Res"},{"issue":"14","key":"3154_CR19","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.3390\/cells12141889","volume":"12","author":"AG Gravina","year":"2023","unstructured":"Gravina AG, Pellegrino R, Durante T, et al. The melanocortin system in inflammatory bowel diseases: insights into its mechanisms and therapeutic potentials. Cells. 2023;12(14):1889. https:\/\/doi.org\/10.3390\/cells12141889.","journal-title":"Cells"},{"key":"3154_CR20","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1055\/s-0035-1556590","volume":"41","author":"E Senchenkova","year":"2015","unstructured":"Senchenkova E, Seifert H, Granger DN. Hypercoagulability and platelet abnormalities in inflammatory bowel disease. Semin Thromb Hemost. 2015;41:582\u20139. https:\/\/doi.org\/10.1055\/s-0035-1556590.","journal-title":"Semin Thromb Hemost"},{"key":"3154_CR21","doi-asserted-by":"publisher","unstructured":"Perez TM, S\u00e1nchez MB, Etchevers MJ, et al. Prevalencia de eventos tromb\u00f3ticos en pacientes con enfermedad inflamatoria intestinal con seguimiento en un centro de referencia de la Ciudad de Buenos Aires. Estudio de corte transversal. Acta Gastroenterol Latinoam. 2022;52:58\u201363. https:\/\/doi.org\/10.52787\/agl.v52i1.171.","DOI":"10.52787\/agl.v52i1.171"},{"key":"3154_CR22","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1111\/joim.12296","volume":"276","author":"L Badimon","year":"2014","unstructured":"Badimon L, Vilahur G. Thrombosis formation on atherosclerotic lesions and plaque rupture. J Intern Med. 2014;276:618\u201332. https:\/\/doi.org\/10.1111\/joim.12296.","journal-title":"J Intern Med"},{"key":"3154_CR23","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1161\/CIRCRESAHA.118.311098","volume":"124","author":"P Libby","year":"2019","unstructured":"Libby P, Pasterkamp G, Crea F, Jang IK. Reassessing the mechanisms of acute coronary syndromes. Circ Res. 2019;124:150\u201360. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311098.","journal-title":"Circ Res"},{"issue":"3","key":"3154_CR24","first-page":"181","volume":"24","author":"AP Agouridis","year":"2011","unstructured":"Agouridis AP, Elisaf M, Milionis HJ. An overview of lipid abnormalities in patients with inflammatory bowel disease. Ann Gastroenterol. 2011;24(3):181\u20137.","journal-title":"Ann Gastroenterol"},{"key":"3154_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpc.2021.100171","volume":"6","author":"T Agrawal","year":"2021","unstructured":"Agrawal T, Acquah I, Dey AK, et al. Prevalence of cardiovascular risk factors in a nationally representative adult population with inflammatory bowel disease without atherosclerotic cardiovascular disease. Am J Prev Cardiol. 2021;6: 100171. https:\/\/doi.org\/10.1016\/j.ajpc.2021.100171.","journal-title":"Am J Prev Cardiol"},{"key":"3154_CR26","doi-asserted-by":"publisher","first-page":"1615","DOI":"10.1093\/eurjpc\/zwad124","volume":"30","author":"JAM Sleutjes","year":"2023","unstructured":"Sleutjes JAM, van der Woude CJ, Verploegh PJP, et al. Cardiovascular risk profiles in patients with inflammatory bowel disease differ from matched controls from the general population. Eur J Prev Cardiol. 2023;30:1615\u201322. https:\/\/doi.org\/10.1093\/eurjpc\/zwad124.","journal-title":"Eur J Prev Cardiol"},{"key":"3154_CR27","doi-asserted-by":"publisher","first-page":"1198988","DOI":"10.3389\/fmed.2023.1198988","volume":"10","author":"H Chen","year":"2023","unstructured":"Chen H, Li W, Hu J, et al. Association of serum lipids with inflammatory bowel disease: a systematic review and meta-analysis. Front Med (Lausanne). 2023;10:1198988. https:\/\/doi.org\/10.3389\/fmed.2023.1198988.","journal-title":"Front Med (Lausanne)"},{"key":"3154_CR28","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11926-018-0715-7","volume":"20","author":"J Plutzky","year":"2018","unstructured":"Plutzky J, Liao KP. Lipids in RA: is less not necessarily more? Curr Rheumatol Rep. 2018;20:8. https:\/\/doi.org\/10.1007\/s11926-018-0715-7.","journal-title":"Curr Rheumatol Rep"},{"key":"3154_CR29","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.addr.2020.10.006","volume":"159","author":"S Nazir","year":"2020","unstructured":"Nazir S, Jankowski V, Bender G, et al. Interaction between high-density lipoproteins and inflammation: function matters more than concentration! Adv Drug Deliv Rev. 2020;159:94\u2013119. https:\/\/doi.org\/10.1016\/j.addr.2020.10.006.","journal-title":"Adv Drug Deliv Rev"},{"key":"3154_CR30","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12944-016-0258-8","volume":"15","author":"CA Forbes","year":"2016","unstructured":"Forbes CA, Quek RG, Deshpande S, et al. The relationship between Lp(a) and CVD outcomes: a systematic review. Lipids Health Dis. 2016;15:95. https:\/\/doi.org\/10.1186\/s12944-016-0258-8.","journal-title":"Lipids Health Dis"},{"key":"3154_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105689","volume":"169","author":"G Reyes-Soffer","year":"2021","unstructured":"Reyes-Soffer G, Westerterp M. Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation. Pharmacol Res. 2021;169:105689. https:\/\/doi.org\/10.1016\/j.phrs.2021.105689.","journal-title":"Pharmacol Res"},{"issue":"12","key":"3154_CR32","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1097\/00042737-200112000-00004","volume":"13","author":"IE Koutroubakis","year":"2001","unstructured":"Koutroubakis IE, Malliaraki N, Vardas E, et al. Increased levels of lipoprotein (a) in Crohn\u2019s disease: a relation to thrombosis? Eur J Gastroenterol Hepatol. 2001;13(12):1415\u20139. https:\/\/doi.org\/10.1097\/00042737-200112000-00004.","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"9","key":"3154_CR33","doi-asserted-by":"publisher","first-page":"834","DOI":"10.3760\/cma.j.cn112138-20200930-00847","volume":"60","author":"D Wang","year":"2021","unstructured":"Wang D, Zhao XJ, Cui XF, Li LZ, Zhang HJ. Correlation of serum lipid profile and disease activity in patients with inflammatory bowel disease. Zhonghua Nei Ke Za Zhi. 2021;60(9):834\u20136. https:\/\/doi.org\/10.3760\/cma.j.cn112138-20200930-00847.","journal-title":"Zhonghua Nei Ke Za Zhi"},{"issue":"1","key":"3154_CR34","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s40119-024-00353-w","volume":"13","author":"H Thau","year":"2024","unstructured":"Thau H, Neuber S, Emmert MY, et al. Targeting lipoprotein(a): can RNA therapeutics provide the next step in the prevention of cardiovascular disease? Cardiol Ther. 2024;13(1):39\u201367. https:\/\/doi.org\/10.1007\/s40119-024-00353-w.","journal-title":"Cardiol Ther"},{"key":"3154_CR35","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jacc.2021.02.009","volume":"77","author":"MS Garshick","year":"2021","unstructured":"Garshick MS, Ward NL, Krueger JG, Berger JS. Cardiovascular risk in patients with psoriasis: JACC review topic of the week. J Am Coll Cardiol. 2021;77:1670\u201380. https:\/\/doi.org\/10.1016\/j.jacc.2021.02.009.","journal-title":"J Am Coll Cardiol"},{"key":"3154_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1093\/ajh\/hpae098","volume":"37","author":"S Akhtari","year":"2024","unstructured":"Akhtari S, Harvey PJ, Eder L. Cardio-rheumatology insights into hypertension: intersection of inflammation, arteries, and heart. Am J Hypertens. 2024;37:933\u201342. https:\/\/doi.org\/10.1093\/ajh\/hpae098.","journal-title":"Am J Hypertens"},{"key":"3154_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/ueg2.12351","volume":"11","author":"J He","year":"2023","unstructured":"He J, Zhang S, Qiu Y, et al. Ulcerative colitis increases risk of hypertension in a UK biobank cohort study. Unit Eur Gastroenterol J. 2023;11:19\u201330. https:\/\/doi.org\/10.1002\/ueg2.12351.","journal-title":"Unit Eur Gastroenterol J"},{"key":"3154_CR38","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1161\/circulationaha.114.009990","volume":"130","author":"A Dregan","year":"2014","unstructured":"Dregan A, Charlton J, Chowienczyk P, Gulliford MC. Chronic inflammatory disorders and risk of type\u00a02 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation. 2014;130:837\u201344. https:\/\/doi.org\/10.1161\/circulationaha.114.009990.","journal-title":"Circulation"},{"key":"3154_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1016\/j.cgh.2019.07.052","volume":"18","author":"T Jess","year":"2020","unstructured":"Jess T, Jensen BW, Andersson M, Villumsen M, Allin KH. Infammatory bowel diseases increase risk of type\u00a02 diabetes in a nationwide cohort study. Clin Gastroenterol Hepatol. 2020;18:881-888.e881. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.052.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3154_CR40","doi-asserted-by":"publisher","first-page":"343","DOI":"10.3390\/jcm8030343","volume":"8","author":"EA Kang","year":"2019","unstructured":"Kang EA, Han K, Chun J, et al. Increased risk of diabetes in inflammatory bowel disease patients: a nationwide population-based study in Korea. J Clin Med. 2019;8:343. https:\/\/doi.org\/10.3390\/jcm8030343.","journal-title":"J Clin Med"},{"key":"3154_CR41","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s00592-024-02254-9","volume":"61","author":"Y Niu","year":"2024","unstructured":"Niu Y, Zhang Q, Wei Y. Causal effects of inflammatory bowel disease on risk of type\u00a02 diabetes: a two-sample multivariable Mendelian randomization study. Acta Diabetol. 2024;61:715\u201324. https:\/\/doi.org\/10.1007\/s00592-024-02254-9.","journal-title":"Acta Diabetol"},{"key":"3154_CR42","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/j.cgh.2019.09.016","volume":"8","author":"SW Lai","year":"2020","unstructured":"Lai SW, Kuo YH, Liao KF. Association between inflammatory bowel disease and diabetes mellitus. Clin Gastroenterol Hepatol. 2020;8:1002\u20133. https:\/\/doi.org\/10.1016\/j.cgh.2019.09.016.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"3154_CR43","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1007\/s10620-024-08504-8","volume":"69","author":"M Mahmoud","year":"2024","unstructured":"Mahmoud M, Syn WK. Impact of obesity and metabolic syndrome on IBD outcomes. Dig Dis Sci. 2024;69(8):2741\u201353. https:\/\/doi.org\/10.1007\/s10620-024-08504-8.","journal-title":"Dig Dis Sci"},{"key":"3154_CR44","doi-asserted-by":"publisher","unstructured":"Fuschillo G, Celentano V, Rottoli M, et al. Influence of diabetes mellitus on inflammatory bowel disease course and treatment outcomes. A systematic review with meta-analysis. Dig Liver Dis. 2023;55(5):580\u2013586. https:\/\/doi.org\/10.1016\/j.dld.2022.08.017.","DOI":"10.1016\/j.dld.2022.08.017"},{"issue":"8","key":"3154_CR45","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.crohns.2014.02.002","volume":"8","author":"GC Parkes","year":"2014","unstructured":"Parkes GC, Whelan K, Lindsay JO. Smoking in inflammatory bowel disease: impact on disease course and insights into the aetiology of its effect. J Crohns Colitis. 2014;8(8):717\u201325. https:\/\/doi.org\/10.1016\/j.crohns.2014.02.002.","journal-title":"J Crohns Colitis"},{"key":"3154_CR46","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.4065\/81.11.1462","volume":"81","author":"SS Mahid","year":"2006","unstructured":"Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S. Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clin Proc. 2006;81:1462\u2013671. https:\/\/doi.org\/10.4065\/81.11.1462.","journal-title":"Mayo Clin Proc"},{"key":"3154_CR47","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/s12916-019-1351-4","volume":"17","author":"E Banks","year":"2019","unstructured":"Banks E, Joshy G, Korda RJ, et al. Tobacco smoking and risk of 36 cardiovascular disease subtypes: fatal and non-fatal outcomes in a large prospective Australian study. BMC Med. 2019;17:128\u2013128. https:\/\/doi.org\/10.1186\/s12916-019-1351-4.","journal-title":"BMC Med"},{"key":"3154_CR48","doi-asserted-by":"publisher","unstructured":"Neal WN, Jones CD, Pekmezi D, Motl RW. Physical activity in adults with Crohn\u2019s disease: a scoping review. Crohns Colitis 360. 2022;4:otac022. https:\/\/doi.org\/10.1093\/crocol\/otac022.","DOI":"10.1093\/crocol\/otac022"},{"issue":"41","key":"3154_CR49","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.3748\/wjg.v29.i41.5668","volume":"29","author":"AG Gravina","year":"2023","unstructured":"Gravina AG, Pellegrino R, Durante T, et al. Inflammatory bowel diseases patients suffer from significant low levels and barriers to physical activity: the \u201cBE-FIT-IBD\u201d study. World J Gastroenterol. 2023;29(41):5668\u201382. https:\/\/doi.org\/10.3748\/wjg.v29.i41.5668.","journal-title":"World J Gastroenterol"},{"key":"3154_CR50","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1016\/j.gastrohep.2023.12.008","volume":"47","author":"E Dom\u00e8nech","year":"2024","unstructured":"Dom\u00e8nech E, Ciudin A, Balibrea JM, et al. Recommendations on the management of severe obesity in patients with inflammatory bowel disease of the Spanish Group on Crohn\u2019s Disease and Ulcerative Colitis (GETECCU), Spanish Society of Obesity (SEEDO), Spanish Association of Surgery (AEC) and Spanish Society of Digestive Endoscopy (SEED). Gastroenterol Hepatol. 2024;47:906\u201323. https:\/\/doi.org\/10.1016\/j.gastrohep.2023.12.008.","journal-title":"Gastroenterol Hepatol"},{"key":"3154_CR51","doi-asserted-by":"publisher","first-page":"20303","DOI":"10.1038\/srep20303","volume":"6","author":"FJ Alenghat","year":"2016","unstructured":"Alenghat FJ. The prevalence of atherosclerosis in those with inflammatory connective tissue disease by race, age, and traditional risk factors. Sci Rep. 2016;6:20303. https:\/\/doi.org\/10.1038\/srep20303.","journal-title":"Sci Rep"},{"key":"3154_CR52","doi-asserted-by":"publisher","unstructured":"Cohen-Heyman\u00a0N,\u00a0Chodick\u00a0G. Inflammatory bowel disease is associated with an increased risk of cardiovascular events in a sex and age-dependent manner: a historical cohort study. Int J Cardiol Cardiovasc Risk Prev.\u00a02025:24:200363. https:\/\/doi.org\/10.1016\/j.ijcrp.2025.200363.","DOI":"10.1016\/j.ijcrp.2025.200363"},{"key":"3154_CR53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.117.005892","volume":"6","author":"W Feng","year":"2017","unstructured":"Feng W, Chen G, Cai D, Zhao S, Cheng J, Shen H. Inflammatory bowel disease and risk of ischemic heart disease: an updated meta-analysis of cohort studies. J Am Heart Assoc. 2017;6:e005892. https:\/\/doi.org\/10.1161\/JAHA.117.005892.","journal-title":"J Am Heart Assoc"},{"key":"3154_CR54","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1177\/2047487318792952","volume":"25","author":"HH Sun","year":"2018","unstructured":"Sun HH, Tian F. Inflammatory bowel disease and cardiovascular disease incidence and mortality: a meta-analysis. Eur J Prev Cardiol. 2018;25:1623\u201331. https:\/\/doi.org\/10.1177\/2047487318792952.","journal-title":"Eur J Prev Cardiol"},{"key":"3154_CR55","doi-asserted-by":"publisher","unstructured":"Zaka A, Mridha N, Subhaharan D, et al. Inflammatory bowel disease patients have an increased risk of acute coronary syndrome: a systematic review and meta-analysis. Open Heart. 2023;10:e002483. https:\/\/doi.org\/10.1136\/openhrt-2023-002483.","DOI":"10.1136\/openhrt-2023-002483"},{"key":"3154_CR56","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/1751-2980.13232","volume":"24","author":"J Wan","year":"2023","unstructured":"Wan J, Wang X, Zhang YJ, et al. Incidence and disease-related risk factors for cerebrovascular accidents in patients with inflammatory bowel diseases: a systematic review and meta-analysis. J Dig Dis. 2023;24:504\u201315. https:\/\/doi.org\/10.1111\/1751-2980.13232.","journal-title":"J Dig Dis"},{"key":"3154_CR57","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.ijcard.2023.02.042","volume":"378","author":"F D\u2019Ascenzo","year":"2023","unstructured":"D\u2019Ascenzo F, Bruno F, Iannaccone M, et al. Patients with inflammatory bowel disease are at increased risk of atherothrombotic disease: a systematic review with meta-analysis. Int J Cardiol. 2023;378:96\u2013104. https:\/\/doi.org\/10.1016\/j.ijcard.2023.02.042.","journal-title":"Int J Cardiol"},{"key":"3154_CR58","first-page":"204","volume":"20","author":"P Sinh","year":"2024","unstructured":"Sinh P, Cross RK. Cardiovascular comorbidities and inflammatory bowel disease: causes and consequences. Gastroenterol Hepatol (N Y). 2024;20:204\u201315.","journal-title":"Gastroenterol Hepatol (N Y)"},{"issue":"24","key":"3154_CR59","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.114.014310","volume":"131","author":"L Fern\u00e1ndez-Friera","year":"2015","unstructured":"Fern\u00e1ndez-Friera L, Pe\u00f1alvo JL, Fern\u00e1ndez-Ortiz A, et al. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) Study. Circulation. 2015;131(24):2104\u201313. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.014310.","journal-title":"Circulation"},{"key":"3154_CR60","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3390\/jcm10081671","volume":"10","author":"A Hern\u00e1ndez-Camba","year":"2021","unstructured":"Hern\u00e1ndez-Camba A, Carrillo-Palau M, Ramos L, et al. Carotid plaque assessment reclassifies patients with inflammatory bowel disease into very-high cardiovascular risk. J Clin Med. 2021;10:1671. https:\/\/doi.org\/10.3390\/jcm10081671.","journal-title":"J Clin Med"},{"key":"3154_CR61","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.3390\/jcm10184102","volume":"10","author":"M Carrillo-Palau","year":"2021","unstructured":"Carrillo-Palau M, Hern\u00e1ndez-Camba A, Ramos L, et al. QRISK3 performance in the assessment of cardiovascular risk in patients with inflammatory bowel disease. J Clin Med. 2021;10:4102. https:\/\/doi.org\/10.3390\/jcm10184102.","journal-title":"J Clin Med"},{"key":"3154_CR62","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ahj.2023.08.011","volume":"266","author":"R Naami","year":"2023","unstructured":"Naami R, Tashtish N, Neeland IJ, et al. Coronary artery calcium scoring for cardiovascular risk assessment in patients with inflammatory bowel disease. Am Heart J. 2023;266:120\u20137. https:\/\/doi.org\/10.1016\/j.ahj.2023.08.011.","journal-title":"Am Heart J"},{"key":"3154_CR63","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.dld.2024.07.019","volume":"56","author":"O Iqbal","year":"2024","unstructured":"Iqbal O, Shah H, Sosa A, Kulinski J, Cross RK, Sinh P. Coronary artery calcium score for cardiovascular risk assessment in inflammatory bowel disease\u2014data from first pilot prospective study. Dig Liver Dis. 2024;56:1965\u20137. https:\/\/doi.org\/10.1016\/j.dld.2024.07.019.","journal-title":"Dig Liver Dis"},{"issue":"5","key":"3154_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2024.102233","volume":"29","author":"R Ghazal","year":"2024","unstructured":"Ghazal R, Bawa D, Ahmed A, et al. The zero calcium score paradox. JACC Case Rep. 2024;29(5):102233. https:\/\/doi.org\/10.1016\/j.jaccas.2024.102233.","journal-title":"JACC Case Rep"},{"issue":"1","key":"3154_CR65","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1001\/jamacardio.2021.4406","volume":"7","author":"MB Mortensen","year":"2022","unstructured":"Mortensen MB, Gaur S, Frimmer A, et al. Association of age with the diagnostic value of coronary artery calcium score for ruling out coronary stenosis in symptomatic patients. JAMA Cardiol. 2022;7(1):36\u201344. https:\/\/doi.org\/10.1001\/jamacardio.2021.4406.","journal-title":"JAMA Cardiol"},{"key":"3154_CR66","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1177\/0003319716652031","volume":"68","author":"GC Wu","year":"2017","unstructured":"Wu GC, Leng RX, Lu Q, Fan YG, Wang DG, Ye DQ. Subclinical atherosclerosis in patients with inflammatory bowel diseases: a systematic review and meta-analysis. Angiology. 2017;68:447\u201361. https:\/\/doi.org\/10.1177\/0003319716652031.","journal-title":"Angiology"},{"key":"3154_CR67","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3390\/biology11030355","volume":"11","author":"M Konwerski","year":"2022","unstructured":"Konwerski M, G\u0105secka A, Opolski G, Grabowski M, Mazurek T. Role of epicardial adipose tissue in cardiovascular diseases: a review. Biology (Basel). 2022;11:355. https:\/\/doi.org\/10.3390\/biology11030355.","journal-title":"Biology (Basel)"},{"key":"3154_CR68","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.reumae.2022.10.003","volume":"19","author":"W Masson","year":"2023","unstructured":"Masson W, Lavalle-Cobo A, Barbagelata B, Lobo M, Nogueira JP. Relationship between epicardial adipose tissue, systemic inflammatory diseases, and subclinical atheromatosis: a systematic review. Reumatol Clin (Engl Ed). 2023;19:363\u201373. https:\/\/doi.org\/10.1016\/j.reumae.2022.10.003.","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"3154_CR69","doi-asserted-by":"publisher","first-page":"4","DOI":"10.14744\/nci.2017.74508","volume":"4","author":"K Ozdil","year":"2017","unstructured":"Ozdil K, Caliskan Z, Keles N, et al. Echocardiographic epicardial fat thickness measurement: a new screening test for subclinic atherosclerosis in patients with inflammatory bowel diseases. North Clin Istanb. 2017;4:4\u201312. https:\/\/doi.org\/10.14744\/nci.2017.74508.","journal-title":"North Clin Istanb"},{"key":"3154_CR70","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.7863\/ultra.14.09040","volume":"35","author":"F Uysal","year":"2016","unstructured":"Uysal F, Akbal E, Akbal A, Cevizci S, Ar\u0131k K, Gazi E. Epicardial adipose tissue is increased in patients with inflammatory bowel disease. J Ultrasound Med. 2016;35:1859\u201364. https:\/\/doi.org\/10.7863\/ultra.14.09040.","journal-title":"J Ultrasound Med"},{"key":"3154_CR71","doi-asserted-by":"publisher","first-page":"643","DOI":"10.17235\/reed.2020.7394\/2020","volume":"113","author":"N Ekmen","year":"2021","unstructured":"Ekmen N, Can G, Yozgat A, et al. Evaluation of epicardial adipose tissue and carotid intima-media thickness as a marker of atherosclerosis in patients with inflammatory bowel disease. Rev Esp Enferm Dig. 2021;113:643\u2013618. https:\/\/doi.org\/10.17235\/reed.2020.7394\/2020.","journal-title":"Rev Esp Enferm Dig"},{"key":"3154_CR72","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/j.jacc.2019.03.009","volume":"74","author":"DK Arnett","year":"2019","unstructured":"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC\/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;74:1376\u2013414. https:\/\/doi.org\/10.1016\/j.jacc.2019.03.009.","journal-title":"J Am Coll Cardiol"},{"key":"3154_CR73","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"key":"3154_CR74","unstructured":"Sociedad Argentina de Cardiolog\u00eda. \u00c1rea de normas y consensos. Riesgo cardiovascular en las enfermedades inflamatorias cr\u00f3nicas. Rev Arg Cardiol. 2019;87:Suppl 2."},{"key":"3154_CR75","doi-asserted-by":"publisher","unstructured":"Mar\u00edn-Jim\u00e9nez I, Carpio D, Hern\u00e1ndez V, et al. Spanish Working Group in Crohn\u00b4s disease and ulcerative colitis (GETECCU) position paper on cardiovascular disease in patients with inflammatory bowel disease.Gastroenterol Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.gastrohep.2024.502314.","DOI":"10.1016\/j.gastrohep.2024.502314"},{"key":"3154_CR76","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ecco-jcc\/jjad108","volume":"18","author":"H Gordon","year":"2024","unstructured":"Gordon H, Burisch J, Ellul P, et al. ECCO guidelines on extraintestinal manifestations in inflammatory bowel disease. J Crohns Colitis. 2024;18:1\u201337. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad108.","journal-title":"J Crohns Colitis"},{"key":"3154_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0308533","volume":"19","author":"D Karacabeyli","year":"2024","unstructured":"Karacabeyli D, Lacaille D, Lu N, et al. Mortality and major adverse cardiovascular events after glucagon-like peptide-1 receptor agonist initiation in patients with immune-mediated inflammatory diseases and type\u00a02 diabetes: a population-based study. PLoS ONE. 2024;19:e0308533. https:\/\/doi.org\/10.1371\/journal.pone.0308533.","journal-title":"PLoS ONE"},{"key":"3154_CR78","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izae090","author":"A Desai","year":"2024","unstructured":"Desai A, Khataniar H, Hashash JG, Farraye FA, Regueiro M, Kochhar GS. Effectiveness and safety of semaglutide for weight loss in patients with inflammatory bowel disease and obesity. Inflamm Bowel Dis. 2024. https:\/\/doi.org\/10.1093\/ibd\/izae090.","journal-title":"Inflamm Bowel Dis"},{"key":"3154_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0056944","volume":"8","author":"SL Kristensen","year":"2013","unstructured":"Kristensen SL, Ahlehoff O, Lindhardsen J, et al. Disease activity in inflammatory bowel disease is associated with increased risk of myocardial infarction, stroke and cardiovascular death\u2014a Danish nationwide cohort study. PLoS ONE. 2013;8:e56944. https:\/\/doi.org\/10.1371\/journal.pone.0056944.","journal-title":"PLoS ONE"},{"key":"3154_CR80","doi-asserted-by":"publisher","DOI":"10.1007\/s00392-024-02503-5","author":"M Fenski","year":"2024","unstructured":"Fenski M, Abazi E, Gr\u00f6schel J, et al. Cardiovascular magnetic resonance reveals myocardial involvement in patients with active stage of inflammatory bowel disease. Clin Res Cardiol. 2024. https:\/\/doi.org\/10.1007\/s00392-024-02503-5.","journal-title":"Clin Res Cardiol"},{"key":"3154_CR81","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1136\/gutjnl-2012-303285","volume":"62","author":"C Rungoe","year":"2013","unstructured":"Rungoe C, Basit S, Ranthe MF, Wohlfahrt J, Langholz E, Jess T. Risk of ischaemic heart disease in patients with inflammatory bowel disease: a nationwide Danish cohort study. Gut. 2013;62:689\u201394. https:\/\/doi.org\/10.1136\/gutjnl-2012-303285.","journal-title":"Gut"},{"key":"3154_CR82","doi-asserted-by":"publisher","unstructured":"Kirchgesner J, Nyboe Andersen N, Carrat F, Jess T, Beaugerie L, for the BERENICE Study Group. Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study. Gut 2020;69:852\u2013858. https:\/\/doi.org\/10.1136\/gutjnl-2019-318932.","DOI":"10.1136\/gutjnl-2019-318932"},{"key":"3154_CR83","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386:316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"issue":"11","key":"3154_CR84","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1001\/jamadermatol.2020.2977","volume":"156","author":"F Poizeau","year":"2020","unstructured":"Poizeau F, Nowak E, Kerbrat S, et al. Association between early severe cardiovascular events and the initiation of treatment with the anti-interleukin 12\/23p40 antibody ustekinumab. JAMA Dermatol. 2020;156(11):1208\u201315. https:\/\/doi.org\/10.1001\/jamadermatol.2020.2977.","journal-title":"JAMA Dermatol"},{"key":"3154_CR85","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cgh.2023.09.033","volume":"22","author":"SS Mattay","year":"2024","unstructured":"Mattay SS, Zamani M, Saturno D, et al. Risk of major adverse cardiovascular events in immune-mediated inflammatory disorders on biologics and small molecules: network meta-analysis. Clin Gastroenterol Hepatol. 2024;22:961-970.e12. https:\/\/doi.org\/10.1016\/j.cgh.2023.09.033.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"3154_CR86","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1080\/17474124.2023.2194631","volume":"17","author":"M Shehab","year":"2023","unstructured":"Shehab M, Alrashed F, Alkazemi A, et al. Impact of biologic therapies and small molecules on the risk of major adverse cardiovascular events in patients with inflammatory bowel diseases: systematic review and meta-analysis of randomized controlled trials. Expert Rev Gastroenterol Hepatol. 2023;17:469\u201377. https:\/\/doi.org\/10.1080\/17474124.2023.2194631.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"3154_CR87","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT04743518?term=NCT04743518.&rank=1. Accessed 28 Jan 2025."},{"key":"3154_CR88","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05112263?term=NCT05112263&rank=1. Accessed 28 Jan 2025."},{"key":"3154_CR89","unstructured":"https:\/\/clinicaltrials.gov\/study\/NCT05781737?cond=IBD-Inflammatory%20Bowel%20Disease&term=cardiovascular&page=2&rank=18. Accessed 28 Jan 2025."},{"key":"3154_CR90","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijcard.2018.06.111","volume":"274","author":"E Ikdahl","year":"2019","unstructured":"Ikdahl E, Wibetoe G, Rollefstad S, et al. Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases. Int J Cardiol. 2019;274:311\u20138. https:\/\/doi.org\/10.1016\/j.ijcard.2018.06.111.","journal-title":"Int J Cardiol"},{"key":"3154_CR91","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/ibd.20266","volume":"14","author":"L Selby","year":"2008","unstructured":"Selby L, Kane S, Wilson J, et al. Receipt of preventive health services by IBD patients is significantly lower than by primary care patients. Inflamm Bowel Dis. 2008;14:253\u20138. https:\/\/doi.org\/10.1002\/ibd.20266.","journal-title":"Inflamm Bowel Dis"},{"key":"3154_CR92","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s10620-010-1329-8","volume":"56","author":"L Selby","year":"2011","unstructured":"Selby L, Hoellein A, Wilson JF. Are primary care providers uncomfortable providing routine preventive care for inflammatory bowel disease patients? Dig Dis Sci. 2011;56:819\u201324. https:\/\/doi.org\/10.1007\/s10620-010-1329-8.","journal-title":"Dig Dis Sci"},{"key":"3154_CR93","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/rheumatology\/keaa209","volume":"60","author":"RE Costello","year":"2021","unstructured":"Costello RE, Yimer BB, Roads P, Jani M, Dixon WG. Glucocorticoid use is associated with an increased risk of hypertension. Rheumatology (Oxford). 2021;60:132\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keaa209.","journal-title":"Rheumatology (Oxford)"},{"key":"3154_CR94","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1159\/000365892","volume":"65","author":"XX Liu","year":"2014","unstructured":"Liu XX, Zhu XM, Miao Q, Ye HY, Zhang ZY, Li YM. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65:324\u201332. https:\/\/doi.org\/10.1159\/000365892.","journal-title":"Ann Nutr Metab"},{"key":"3154_CR95","doi-asserted-by":"publisher","unstructured":"Sleutjes JAM, Roeters van Lennep JE, Boersma E, et al. Systematic review with meta-analysis: effect of inflammatory bowel disease therapy on lipid levels. Aliment Pharmacol Ther. 2021;54:999\u20131012. https:\/\/doi.org\/10.1111\/apt.16580.","DOI":"10.1111\/apt.16580"},{"key":"3154_CR96","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.3748\/wjg.v27.i40.6757","volume":"27","author":"A Stadnicki","year":"2021","unstructured":"Stadnicki A, Stadnicka I. Venous and arterial thromboembolism in patients with inflammatory bowel diseases. World J Gastroenterol. 2021;27:6757\u201374. https:\/\/doi.org\/10.3748\/wjg.v27.i40.6757.","journal-title":"World J Gastroenterol"},{"key":"3154_CR97","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007893.pub2","author":"N Robert","year":"2010","unstructured":"Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010. https:\/\/doi.org\/10.1002\/14651858.CD007893.pub2.","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"3154_CR98","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1097\/MOL.0000000000000363","volume":"27","author":"M Kockx","year":"2016","unstructured":"Kockx M, Kritharides L. Hyperlipidaemia in immunosuppression. Curr Opin Lipidol. 2016;27(6):631\u20132. https:\/\/doi.org\/10.1097\/MOL.0000000000000363.","journal-title":"Curr Opin Lipidol"},{"key":"3154_CR99","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.1161\/CIR.0000000000000426","volume":"134","author":"RL Page","year":"2016","unstructured":"Page RL, O\u2019Bryant CL, Cheng D, et al. Drugs that may cause or exacerbate heart failure: a scientific statement from the American Heart Association. Circulation. 2016;134:e32-69. https:\/\/doi.org\/10.1161\/CIR.0000000000000426.","journal-title":"Circulation"},{"issue":"6","key":"3154_CR100","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/ibd\/izaa227","volume":"27","author":"BE Sands","year":"2021","unstructured":"Sands BE, Colombel JF, Ha C, et al. Lipid profiles in patients with ulcerative colitis receiving tofacitinib-implications for cardiovascular risk and patient management. Inflamm Bowel Dis. 2021;27(6):797\u2013808.","journal-title":"Inflamm Bowel Dis"},{"key":"3154_CR101","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.cgh.2023.11.018","volume":"22","author":"A Armuzzi","year":"2024","unstructured":"Armuzzi A, Cross RK, Lichtenstein GR, et al. Cardiovascular safety of ozanimod in patients with ulcerative colitis: true north and open-label extension analyses. Clin Gastroenterol Hepatol. 2024;22:1067-1076.e3. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.018.","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03154-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03154-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T02:51:07Z","timestamp":1744858267000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03154-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,27]]},"references-count":101,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["3154"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03154-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,27]]},"assertion":[{"value":"13 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Walter Masson, Gonzalo Fern\u00e1ndez-Villar, and Solange Martinez-Elhelou have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}